Evidence map›Paper›PMID 32669383›Full record

ArticleJournal of lipid research2020

Interleukin 6 reduces allopregnanolone synthesis in the brain and contributes to age-related cognitive decline in mice.

Eileen E Parks, Sreemathi Logan, Alexander Yeganeh, Julie A Farley, Daniel B Owen, William E Sonntag

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Allopregnanolone: Metabolism, Mechanisms of Action, and Its Role in Cancer.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eileen E ParksOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Sreemathi LoganOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Alexander YeganehOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Julie A FarleyOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Daniel B OwenOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
William E SonntagOklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA William-Sonntag@ouhsc.edu.ORCID 0000-0003-1850-2407
University of Oklahoma Health Sciences Center · US

Funding

GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Benjamin Francis Miller, William Edmund Sonntag · 2017 to 2026
$3.6M
IGF-1 Regulation of Astrocyte Mitochondrial Metabolism and Redox Homeostasis in Brain AgingR00AG056662 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LOGAN, SREEMATHI · 2020 to 2022
$996k
Triple Quadrupole - Ion Trap Hybrid LC/MS/MS SystemS10RR027926 · NCRR · WAYNE STATE UNIVERSITY · PI MADDIPATI, KRISHNARAO · 2010 to 2010
$425k
IGF-1 Regulation of Astrocyte Mitochondrial Metabolism and Redox Homeostasis in Brain AgingK99AG056662 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LOGAN, SREEMATHI · 2018 to 2019
$248k
IMPACT OF REDUCED NEUROSTEROIDS IN BRAIN AGINGR36AG058890 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PARKS, EILEEN ELIZABETH · 2018 to 2019
$120k
NCRR NIH HHS S10 RR027926NIA NIH HHS K99 AG056662NIA NIH HHS R00 AG056662NIA NIH HHS R36 AG058890NIA NIH HHS T32 AG052363
6 · The paper itself

Abstract

Cognitive decline with age is a harmful process that can reduce quality of life. Multiple factors have been established to contribute to cognitive decline, but the overall etiology remains unknown. Here, we hypothesized that cognitive dysfunction is mediated, in part, by increased levels of inflammatory cytokines that alter allopregnanolone (AlloP) levels, an important neurosteroid in the brain. We assessed the levels and regulation of AlloP and the effects of AlloP supplementation on cognitive function in 4-month-old and 24-month-old male C57BL/6 mice. With age, the expression of enzymes involved in the AlloP synthetic pathway was decreased and corticosterone (CORT) synthesis increased. Supplementation of AlloP improved cognitive function. Interestingly, interleukin 6 (IL-6) infusion in young animals significantly reduced the production of AlloP compared with controls. It is notable that inhibition of IL-6 with its natural inhibitor, soluble membrane glycoprotein 130, significantly improved spatial memory in aged mice. These findings were supported by in vitro experiments in primary murine astrocyte cultures, indicating that IL-6 decreases production of AlloP and increases CORT levels. Our results indicate that age-related increases in IL-6 levels reduce progesterone substrate availability, resulting in a decline in AlloP levels and an increase in CORT. Furthermore, our results indicate that AlloP is a critical link between inflammatory cytokines and the age-related decline in cognitive function.

Indexed as

AgingBrainCognitive DysfunctionInterleukin-6PregnanoloneAnimalsMaleMiceMice, Inbred C57BLInterleukin-6PregnanoloneagingAlzheimer’s diseasecognitive functionenzyme regulationinflammationneurosteroidprogesteronesteroid hormones

Identifiers

PMID32669383
PMCPMC7529050
OpenAlexW3043605677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.